TCM
NGEN

Traynor Capital Management’s NervGen Pharma NGEN Stock Holding History

Traynor Capital Management’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.9K Buy
31,500
+6,000
+24% +$18.6K ﹤0.01% 351
2026
Q1 		$95.1K Buy
+25,500
New +$110K 0.01% 315

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Traynor Capital Management's NGEN Position: Q2 2026 in Review

Traynor Capital Management increased its NervGen Pharma (NGEN) stake by 24% in Q2 2026, buying an estimated $18.6K and bringing the position to 31,500 shares worth $64.9K. The position accounts for ﹤0.01% of the portfolio, ranked #351.

Traynor Capital Management first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $95.1K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Traynor Capital Management held 31,500 shares of NervGen Pharma worth $64.9K as of Q2 2026.
  • Traynor Capital Management bought 6,000 NervGen Pharma shares in Q2 2026, an estimated $18.6K.
  • NervGen Pharma made up ﹤0.01% of Traynor Capital Management's portfolio in Q2 2026, its #351 holding.
  • Traynor Capital Management first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Traynor Capital Management's NervGen Pharma position peaked at $95.1K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.